200 related articles for article (PubMed ID: 30337444)
1. SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772).
Raghu G; Richeldi L; Crestani B; Wung P; Bejuit R; Esperet C; Antoni C; Soubrane C
Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30337444
[TBL] [Abstract][Full Text] [Related]
2. A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.
Allanore Y; Wung P; Soubrane C; Esperet C; Marrache F; Bejuit R; Lahmar A; Khanna D; Denton CP;
Ann Rheum Dis; 2020 Dec; 79(12):1600-1607. PubMed ID: 32963047
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.
Raghu G; Brown KK; Collard HR; Cottin V; Gibson KF; Kaner RJ; Lederer DJ; Martinez FJ; Noble PW; Song JW; Wells AU; Whelan TP; Wuyts W; Moreau E; Patterson SD; Smith V; Bayly S; Chien JW; Gong Q; Zhang JJ; O'Riordan TG
Lancet Respir Med; 2017 Jan; 5(1):22-32. PubMed ID: 27939076
[TBL] [Abstract][Full Text] [Related]
4. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Santin-Janin H; Mulder GJ; Bartholmai B; Gupta R; Richeldi L
JAMA; 2018 Jun; 319(22):2299-2307. PubMed ID: 29800034
[TBL] [Abstract][Full Text] [Related]
5. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.
Richeldi L; Fernández Pérez ER; Costabel U; Albera C; Lederer DJ; Flaherty KR; Ettinger N; Perez R; Scholand MB; Goldin J; Peony Yu KH; Neff T; Porter S; Zhong M; Gorina E; Kouchakji E; Raghu G
Lancet Respir Med; 2020 Jan; 8(1):25-33. PubMed ID: 31575509
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
7. Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial.
Richeldi L; Schiffman C; Behr J; Inoue Y; Corte TJ; Cottin V; Jenkins RG; Nathan SD; Raghu G; Walsh SLF; Jayia PK; Kamath N; Martinez FJ
Am J Respir Crit Care Med; 2024 May; 209(9):1132-1140. PubMed ID: 38354066
[No Abstract] [Full Text] [Related]
8. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.
Palmer SM; Snyder L; Todd JL; Soule B; Christian R; Anstrom K; Luo Y; Gagnon R; Rosen G
Chest; 2018 Nov; 154(5):1061-1069. PubMed ID: 30201408
[TBL] [Abstract][Full Text] [Related]
9. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab.
Raghu G; Martinez FJ; Brown KK; Costabel U; Cottin V; Wells AU; Lancaster L; Gibson KF; Haddad T; Agarwal P; Mack M; Dasgupta B; Nnane IP; Flavin SK; Barnathan ES
Eur Respir J; 2015 Dec; 46(6):1740-50. PubMed ID: 26493793
[TBL] [Abstract][Full Text] [Related]
10. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
11. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.
Birring SS; Wijsenbeek MS; Agrawal S; van den Berg JWK; Stone H; Maher TM; Tutuncu A; Morice AH
Lancet Respir Med; 2017 Oct; 5(10):806-815. PubMed ID: 28923239
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis.
Maher TM; Costabel U; Glassberg MK; Kondoh Y; Ogura T; Scholand MB; Kardatzke D; Howard M; Olsson J; Neighbors M; Belloni P; Swigris JJ
Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 33008934
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S;
Mod Rheumatol; 2018 Jan; 28(1):76-84. PubMed ID: 28622048
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis.
Rosas IO; Goldberg HJ; Collard HR; El-Chemaly S; Flaherty K; Hunninghake GM; Lasky JA; Lederer DJ; Machado R; Martinez FJ; Maurer R; Teller D; Noth I; Peters E; Raghu G; Garcia JGN; Choi AMK
Chest; 2018 Jan; 153(1):94-104. PubMed ID: 29100885
[TBL] [Abstract][Full Text] [Related]
16. GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial.
Strambu IR; Seemayer CA; Fagard LMA; Ford PA; Van der Aa TAK; de Haas-Amatsaleh AA; Modgill V; Santermans E; Sondag EN; Helmer EG; Maher TM; Costabel U; Cottin V
Eur Respir J; 2023 Mar; 61(3):. PubMed ID: 36328358
[TBL] [Abstract][Full Text] [Related]
17. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
[TBL] [Abstract][Full Text] [Related]
18. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.
King TE; Albera C; Bradford WZ; Costabel U; Hormel P; Lancaster L; Noble PW; Sahn SA; Szwarcberg J; Thomeer M; Valeyre D; du Bois RM;
Lancet; 2009 Jul; 374(9685):222-8. PubMed ID: 19570573
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
